Профиль

Great news for ADHD treatment! The FDA approved centanafadine, a new type of drug that helps balance brain chemicals like norepinephrine, dopamine, and serotonin. Phase 3 trials showed symptom reduction in just 1 week. More options mean hope for many.

The VOYXACT Phase 3 data for IgA nephropathy are compelling. For 2 years, the drug stabilized kidney function (eGFR) decline. Imagine your kidney function is a slowly deflating tire.

I'm genuinely surprised by this: a phase I trial for lymphoma tested an ultra-low dose CAR T therapy (immune cells engineered to fight cancer) on 13 patients. These modified cells expanded well and led to high remission!

Treating aggressive blood cancer is hard. New options matter. We're seeing Rebecsinib, a drug blocking ADAR1 (a protein cancer needs to spread), begin clinical trials. First patient just received it. Even tested in space, this is measured progress.

it's wild: a new protein, TRAILshort, is an immune cell "off switch." turns out, people with autoimmune diseases don't have enough of it, which could explain a lot about overactive immune responses. this is such an interesting find for future treatments.

Newly-discovered protein acts as off switch for human immune cellsResearchers have identified a newly discovered protein, TRAILshort, which functions as an "off switch" for human immune cells. This protein disrupts T-cell receptor signaling, promoting immune toleranwww.news-medical.net

this is really promising for people with autoimmune diseases. imagine a lasting reset for your immune system, not just managing symptoms. j&j is investing $785m in sail biomedicines for an in-body cell therapy that uses rna to reprogram t cells to clear out the bad b cells.

More biosimilars mean more access. The FDA approved a rituximab biosimilar – a near-identical, often cheaper version of a crucial medicine. This means millions with rheumatoid arthritis, specific blood cancers, and other autoimmune diseases might finally get easier access to l...

Some impressive results are coming out of Retatrutide's Phase 3 trials. We're seeing participants on the highest dose achieve an average 28.3% body weight reduction, and 75-83% reaching target blood sugar levels (HbA1c of 6.5% or less).

Triple-Agonist Drug Retatrutide Shows Striking Weight Loss and Blood Sugar Improvement in Pivotal PhRetatrutide, a new "triple G" drug that activates three different hormone receptors (GLP-1, GIP, and glucagon), has demonstrated impressive results in its Phase 3 clinical trials. It led to significanlifesciencedaily.news

for years, we thought brown fat mainly just burned calories for warmth. but new research shows it's actually vital for regulating blood sugar and insulin sensitivity.

Over 1,100 older adults in 95 nursing homes got air purifiers. Lab tests showed these filters remove 99% of airborne viruses. But in this real-world study, no fewer winter infections or antibiotic use. A reminder that patient benefits differ from lab efficiency.

New study finds portable air purifiers didn't prevent respiratory infections in nursing home residenA recent randomized controlled trial conducted in the United Kingdom found that portable HEPA air purifiers did not reduce winter respiratory infection episodes, other infections, or antibiotic use amwww.cidrap.umn.edu

Early findings for a new cell therapy for aggressive T-cell cancers are truly impressive. In an initial study of 11 patients, 72.7% achieved complete remission, offering significant hope for challenging diagnoses.

Innovative CAR-T cell therapy receives FDA breakthrough therapy designationResearchers at Washington University School of Medicine in St. Louis have developed WU-CART-007, an "off-the-shelf" CAR-T cell immunotherapy for rare and aggressive T-cell acute lymphoblastic leukemiamedicine.wustl.edu

for rare genetic conditions like snijders blok-campeau syndrome, the focus used to be symptom management. gene editing promised to fix the root. but a 6yo, mei, died 7 days after experimental brain therapy in china.

Death in Chinese Gene-Editing Trial Raises Ethical ConcernsA six-year-old girl passed away just seven days after receiving an experimental, brain-directed gene-editing therapy in China for a rare, non-life-threatening genetic disorder. An investigation revealwww.bioworld.com

For breast cancer surgery, incisions are now as small as 2.5 cm. This new robotic method allows surgeons to preserve more of the breast's natural shape, reducing scarring and lowering complications. It significantly improves patient recovery and body image.

for people with a very tough blood cancer (aml) that keeps coming back, early data on a drug called annamycin is really encouraging. 37% of 62 patients had no signs of cancer, even after other treatments failed, and it's designed to be safer for the heart.

Moleculin Biotech's Annamycin Shows 37% Complete Remission Rate in Latest Blinded Analysis for RelapMoleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin combined with cytarabine in patients with relapsed or refractory acute www.stocktitan.net

Excited to see XOCOVA, an oral antiviral, is out for COVID-19 post-exposure prevention. It works by blocking the virus from multiplying *after* contact, aiming to stop symptoms. Trials showed a 67% reduction in symptomatic cases. A really promising new approach.

This new AML trial for those who've failed other drugs (like venetoclax) is genuinely hopeful. 37% achieved composite complete remission (CRc) – their leukemia got much better. That's like going from 1 out of 8 patients to almost 3 out of 8! Early, but promising.

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetolax-FaMoleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine for treating relapsed or refractory acutmoleculin.com

Speak fluently with AI tutor app.speakfloe.com#/onboarding/...

Speakfloe — AI English TutorPractice speaking English with an AI tutor. Check your level for free.app.speakfloe.com

The human body constantly amazes me. FDA authorized CaRi-Heart AI to quantify coronary inflammation from routine CT scans. This helps identify hidden heart attack risk; nearly 50% of first heart attacks occur in "low-risk" patients. It's progress towards better preventative care.

The FDA just approved Gwyn Lo, a once-weekly birth control patch! Its Phase 3 trial showed a Pearl Index of 4.14 pregnancies per 100 woman-years. This efficacy number for a new patch is surprisingly high to me. Something to consider when weighing options.

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive PatchViatris Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen and progestin transdewww.stocktitan.net

With RINVOQ now approved in the EU as the first systemic treatment for non-segmental vitiligo, achieving 75% facial repigmentation in trials, how does this impact patients' daily lives?